FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 5
Volume 15
Issue 5

FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib

FRAZER, Pennsylvania—The FDA has granted orphan drug status to Cephalon, Inc.'s lestaurtinib (CEP-701) for acute myeloid leukemia (AML). The oral compound inhibits several tyrosine kinases including FLT-3 and TrkA. It is in phase II/III trials for AML patients at first relapse who have a FLT-3 activating mutation.

Articles in this issue
NCCN Soft-Tissue Extremity Sarcoma Guidelines Clarify Follow-up Schedule
Genentech Files sBLA for Avastin for First-Line NSCLC Treatment
RFA Effective for Single, Small Hepatocellular Carcinoma
New Imaging, ChemoRT Recommendations From NCCN
Panitumumab Improves PFS in Advanced Colon Ca
Studies Question Watchful Waiting for Some Prostate Ca Pts
Growing Evidence Supports Stem Cell Hypothesis of Cancer
FDA Approves New Every-3-Week Dosing for Aranesp
Telephone Often Delivers News of Breast Cancer Diagnosis
IND Submitted for CYT-500
Lower-Dose Thalidomide Effective in Relapsed or Refractory Multiple Myeloma, With Less Toxicity
Zometa Increases BMD in Breast Ca Patients on Femara
Prostate Cancer Recurrence Linked to Surgeon's Skill
FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib
Automated Voice System Manages Chemo Symptoms
Recent Videos
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
4 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.

CAR T Therapy Shows Similar Efficacy, Safety in Multiple Myeloma Subgroups

Russ Conroy
February 2nd 2025
Article

Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.

Cetuximab/Radiation Improves DFS in Locally Advanced SCCHN

Russ Conroy
February 1st 2025
Article

Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Psilocybin May Help Address Cancer-Related Psychological Concerns

Michael P. Bogenschutz, MD
January 20th 2025
Podcast

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Incorporating frailty evaluation into practice may alter clinical decision-making for preoperative planning and patient counseling for gynecologic surgery.

Frailty Confers Worse Recovery Outcomes After Gynecologic Surgery

Roman Fabbricatore
January 31st 2025
Article

Incorporating frailty evaluation into practice may alter clinical decision-making for preoperative planning and patient counseling for gynecologic surgery.

Azenosertib Monotherapy Yields Encouraging Responses in Cyclin E1+ PROC

Azenosertib Monotherapy Yields Encouraging Responses in Cyclin E1+ PROC

Tim Cortese
January 31st 2025
Article

Results from the ZN-c3-001, MAMMOTH, and DENALI trials demonstrated meaningful ORRs with azenosertib in platinum-resistant ovarian cancer.